MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 24, 2005--Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed enrollment for the Phase II clinical trial evaluating the safety and efficacy of its Gabapentin extended release tablets to treat patients with postherpetic neuralgia, a long-lasting pain condition associated with nerve damage from herpes zoster, or shingles, infection.
